Chinese approval for Ascletis' HCV drug

Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) said China's State Drug Administration approved an NDA for Ganovo danoprevir to treat HCV. The company intends to launch the product next quarter, according to its website. Ascletis said the drug is the first domestically developed direct-acting antiviral agent.

Ascletis President and CEO Jinzi Wu told BioCentury that the approval is the company's first. He declined to disclose the wholesale acquisition cost (WAC) or launch date...